|
1
|
Wingerchuk DM, Banwell B, Bennett JL,
Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B,
Jacob A, et al: International Panel for NMO Diagnosis.
International consensus diagnostic criteria for neuromyelitis
optica spectrum disorders. Neurology. 85:177–189. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Waters P, Reindl M, Saiz A, Schanda K,
Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, et
al: Multicentre comparison of a diagnostic assay: Aquaporin-4
antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry.
87:1005–1015. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Forsthuber TG, Cimbora DM, Ratchford JN,
Katz E and Stüve O: B cell-based therapies in CNS autoimmunity:
Differentiating CD19 and CD20 as therapeutic targets. Ther Adv
Neurol Disord. 11(1756286418761697)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rastetter W, Molina A and White CA:
Rituximab: Expanding role in therapy for lymphomas and autoimmune
diseases. Annu Rev Med. 55:477–503. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Iorio R, Damato V, Alboini PE and Evoli A:
Efficacy and safety of rituximab for myasthenia gravis: A
systematic review and meta-analysis. J Neurol. 262:1115–1119.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cree BA, Lamb S, Morgan K, Chen A, Waubant
E and Genain C: An open label study of the effects of rituximab in
neuromyelitis optica. Neurology. 64:1270–1272. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jacob A, Weinshenker BG, Violich I,
McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M,
Constantinescu CS, Miller A, et al: Treatment of neuromyelitis
optica with rituximab: Retrospective analysis of 25 patients. Arch
Neurol. 65:1443–1448. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bedi GS, Brown AD, Delgado SR, Usmani N,
Lam BL and Sheremata WA: Impact of rituximab on relapse rate and
disability in neuromyelitis optica. Mult Scler. 17:1225–1230.
2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pellkofer HL, Krumbholz M, Berthele A,
Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld
R and Kuempfel T: Long-term follow-up of patients with
neuromyelitis optica after repeated therapy with rituximab.
Neurology. 76:1310–1315. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sellner J, Boggild M, Clanet M, Hintzen
RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS
and Hemmer B: EFNS guidelines on diagnosis and management of
neuromyelitis optica. Eur J Neurol. 17:1019–1032. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Trebst C, Jarius S, Berthele A, Paul F,
Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O and
Kümpfel T: Neuromyelitis Optica Study Group (NEMOS). Update on the
diagnosis and treatment of neuromyelitis optica: Recommendations of
the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 261:1–16.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Damato V, Evoli A and Iorio R: Efficacy
and safety of rituximab therapy in neuromyelitis optica spectrum
disorders: A systematic review and meta-analysis. JAMA Neurol.
73:1342–1348. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Poupart J, Giovannelli J, Deschamps R,
Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B,
Cohen M, et al: Evaluation of efficacy and tolerability of
first-line therapies in NMOSD. Neurology. 94:e1645–e1656.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nikoo Z, Badihian S, Shaygannejad V,
Asgari N and Ashtari F: Comparison of the efficacy of azathioprine
and rituximab in neuromyelitis optica spectrum disorder: A
randomized clinical trial. J Neurol. 264:2003–2009. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tahara M, Oeda T, Okada K, Kiriyama T,
Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, et al:
Safety and efficacy of rituximab in neuromyelitis optica spectrum
disorders (RIN-1 study): A multicentre, randomised, double-blind,
placebo-controlled trial. Lancet Neurol. 19:298–306.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kim SH, Huh SY, Jang H, Park NY, Kim Y,
Jung JY, Lee MY, Hyun JW and Kim HJ: Outcome of pregnancies after
onset of the neuromyelitis optica spectrum disorder. Eur J Neurol.
27:1546–1555. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kim SH, Huh SY, Lee SJ, Joung A and Kim
HJ: A 5-year follow-up of rituximab treatment in patients with
neuromyelitis optica spectrum disorder. JAMA Neurol. 70:1110–1117.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Marcinnò A, Marnetto F, Valentino P,
Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G and
Bertolotto A: Rituximab-induced hypogammaglobulinemia in patients
with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol
Neuroinflamm. 5(e498)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Luna G, Alping P, Burman J, Fink K,
Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J,
Nilsson P, et al: Infection risks among patients with multiple
sclerosis treated with fingolimod, natalizumab, rituximab, and
injectable therapies. JAMA Neurol. 77:84–191. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Holmøy T, Høglund RA, Illes Z, Myhr KM and
Torkildsen Ø: Recent progress in maintenance treatment of
neuromyelitis optica spectrum disorder. J Neurol: Oct 3, 2020
(Online ahead of print).
|
|
21
|
Chen D, Gallagher S, Monson NL, Herbst R
and Wang Y: Inebilizumab, a B cell-depleting anti-CD19 antibody for
the treatment of autoimmune neurological diseases: Insights from
preclinical studies. J Clin Med. 5(107)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Otero DC, Anzelon AN and Rickert RC: CD19
function in early and late B cell development: I. Maintenance of
follicular and marginal zone B cells requires CD19-dependent
survival signals. J Immunol. 170:73–83. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schiopu E, Chatterjee S, Hsu V, Flor A,
Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, et al:
Safety and tolerability of an anti-CD19 monoclonal antibody,
MEDI-551, in subjects with systemic sclerosis: A phase I,
randomized, placebo-controlled, escalating single-dose study.
Arthritis Res Ther. 18(131)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Agius MA, Klodowska-Duda G, Maciejowski M,
Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E
and Flor A: Safety and tolerability of inebilizumab (MEDI-551), an
anti-CD19 monoclonal antibody, in patients with relapsing forms of
multiple sclerosis: Results from a phase 1 randomised,
placebo-controlled, escalating intravenous and subcutaneous dose
study. Mult Scler. 25:235–245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Paul F, Murphy O, Pardo S and Levy M:
Investigational drugs in development to prevent neuromyelitis
optica relapses. Expert Opin Investig Drugs. 27:265–271.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cree BAC, Bennett JL, Kim HJ, Weinshenker
BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR,
Marignier R, et al: Inebilizumab for the treatment of neuromyelitis
optica spectrum disorder (N-MOmentum): A double-blind, randomised
placebo-controlled phase 2/3 trial. Lancet. 394:1352–1363.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Frampton JE: Inebilizumab: First approval.
Drugs. 80:1259–1264. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Uzawa A, Mori M, Arai K, Sato Y, Hayakawa
S, Masuda S, Taniguchi J and Kuwabara S: Cytokine and chemokine
profiles in neuromyelitis optica: Significance of interleukin-6.
Mult Scler. 16:1443–1452. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chihara N, Aranami T, Sato W, Miyazaki Y,
Miyake S, Okamoto T, Ogawa M, Toda T and Yamamura T: Interleukin 6
signaling promotes anti-aquaporin 4 autoantibody production from
plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA.
108:3701–3706. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fujihara K, Bennett JL, de Seze J,
Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T and
Yamamura T: Interleukin-6 in neuromyelitis optica spectrum disorder
pathophysiology. Neurol Neuroimmunol Neuroinflamm.
7(e841)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bradl M, Kanamori Y, Nakashima I, Misu T,
Fujihara K, Lassmann H and Sandkühler J: Pain in neuromyelitis
optica - prevalence, pathogenesis and therapy. Nat Rev Neurol.
10:529–536. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Araki M, Matsuoka T, Miyamoto K, Kusunoki
S, Okamoto T, Murata M, Miyake S, Aranami T and Yamamura T:
Efficacy of the anti-IL-6 receptor antibody tocilizumab in
neuromyelitis optica: A pilot study. Neurology. 82:1302–1306.
2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kang S, Tanaka T, Narazaki M and Kishimoto
T: Targeting interleukin-6 signaling in clinic. Immunity.
50:1007–1023. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Araki M, Aranami T, Matsuoka T, Nakamura
M, Miyake S and Yamamura T: Clinical improvement in a patient with
neuromyelitis optica following therapy with the anti-IL-6 receptor
monoclonal antibody tocilizumab. Mod Rheumatol. 23:827–831.
2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ayzenberg I, Kleiter I, Schröder A,
Hellwig K, Chan A, Yamamura T and Gold R: Interleukin 6 receptor
blockade in patients with neuromyelitis optica nonresponsive to
anti-CD20 therapy. JAMA Neurol. 70:394–397. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ringelstein M, Ayzenberg I, Harmel J,
Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G,
Stettner M, Chan A, et al: Long-term therapy with interleukin 6
receptor blockade in highly active neuromyelitis optica spectrum
disorder. JAMA Neurol. 72:756–763. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lotan I, Charlson RW, Ryerson LZ, Levy M
and Kister I: Effectiveness of subcutaneous tocilizumab in
neuromyelitis optica spectrum disorders. Mult Scler Relat Disord.
39(101920)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang C, Zhang M, Qiu W, Ma H, Zhang X,
Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, et al: Safety and efficacy
of tocilizumab versus azathioprine in highly relapsing
neuromyelitis optica spectrum disorder (TANGO): An open-label,
multicentre, randomised, phase 2 trial. Lancet Neurol. 19:391–401.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Araki M: Blockade of IL-6 signaling in
neuromyelitis optica. Neurochem Int. 130(104315)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yamamura T, Kleiter I, Fujihara K, Palace
J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A,
Yamazaki H, et al: Trial of satralizumab in neuromyelitis optica
spectrum disorder. N Engl J Med. 381:2114–2124. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Traboulsee A, Greenberg BM, Bennett JL,
Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y,
Wright P, et al: Safety and efficacy of satralizumab monotherapy in
neuromyelitis optica spectrum disorder: A randomised, double-blind,
multicentre, placebo-controlled phase 3 trial. Lancet Neurol.
19:402–412. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lotan I, McGowan R and Levy M: Anti-IL-6
therapies for neuromyelitis optica spectrum disorders: A systematic
review of safety and efficacy. Curr Neuropharmacol: Apr 28, 2020
(Epub ahead of print). doi: 10.2174/1570159X18666200429010825.
|
|
43
|
Rosso M, Saxena S and Chitnis T: Targeting
IL-6 receptor in the treatment of neuromyelitis optica spectrum: A
review of emerging treatment options. Expert Rev Neurother.
20:509–516. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Heo YA: Satralizumab: First approval.
Drugs. 80:1477–1482. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Carpanini SM, Torvell M and Morgan BP:
Therapeutic inhibition of the complement system in diseases of the
central nervous system. Front Immunol. 10(362)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pittock SJ, Lennon VA, McKeon A, Mandrekar
J, Weinshenker BG, Lucchinetti CF, O'Toole O and Wingerchuk DM:
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica
spectrum disorders: An open-label pilot study. Lancet Neurol.
12:554–562. 2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Pittock SJ, Berthele A, Fujihara K, Kim
HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan
S, et al: Eculizumab in aquaporin-4-positive neuromyelitis optica
spectrum disorder. N Engl J Med. 381:614–625. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Frampton JE: Eculizumab: A review in
neuromyelitis optica spectrum disorder. Drugs. 80:719–727.
2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Verkman AS, Smith AJ, Phuan PW,
Tradtrantip L and Anderson MO: The aquaporin-4 water channel as a
potential drug target in neurological disorders. Expert Opin Ther
Targets. 21:1161–1170. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Tradtrantip L, Zhang H, Saadoun S, Phuan
PW, Lam C, Papadopoulos MC, Bennett JL and Verkman AS:
Anti-aquaporin-4 monoclonal antibody blocker therapy for
neuromyelitis optica. Ann Neurol. 71:314–322. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Duan T, Tradtrantip L, Phuan PW, Bennett
JL and Verkman AS: Affinity-matured ‘aquaporumab’ anti-aquaporin-4
antibody for therapy of seropositive neuromyelitis optica spectrum
disorders. Neuropharmacology. 162(107827)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Shimizu F, Sano Y, Takahashi T, Haruki H,
Saito K, Koga M and Kanda T: Sera from neuromyelitis optica
patients disrupt the blood-brain barrier. J Neurol Neurosurg
Psychiatry. 83:288–297. 2012.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Mealy MA, Shin K, John G and Levy M:
Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin
Exp Neuroimmunol. 6:413–418. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Keating GM: Bevacizumab: A review of its
use in advanced cancer. Drugs. 74:1891–1925. 2014.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Mealy MA and Levy M: A pilot safety study
of ublituximab, a monoclonal antibody against CD20, in acute
relapses of neuromyelitis optica spectrum disorder. Medicine
(Baltimore). 98(e15944)2019.PubMed/NCBI View Article : Google Scholar
|
